MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.50
+0.56 (+1.44%)
At close: 4:00PM EDT

39.50 0.00 (0.00%)
After hours: 5:02PM EDT

Stock chart is not supported by your current browser
Previous Close38.94
Open39.10
Bid38.06 x 200
Ask39.60 x 500
Day's Range38.56 - 39.63
52 Week Range29.39 - 47.82
Volume2,892,225
Avg. Volume4,731,288
Market Cap20.334B
Beta1.33
PE Ratio (TTM)30.38
EPS (TTM)1.30
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est49.86
Trade prices are not sourced from all markets
  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realistyesterday

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realistyesterday

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
    PR Newswireyesterday

    Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®

    HERTFORDSHIRE, England and PITTSBURGH, April 25, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz® Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy and for the treatment of acne vulgaris in women at least 14 years of age who have achieved menarche and desire an oral contraceptive for birth control. In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.

  • Reuters2 days ago

    Generic drugmakers to face first charges in U.S. probe - Bbg

    U.S. prosecutors were nearing their first charges against generic-drug companies in a nearly four-year-old criminal probe into a possible price-fixing, Bloomberg reported, citing people familiar with the matter. Soaring drug prices from both branded and generic drugmakers have sparked outrage and investigations in the past, with President Donald Trump last year calling it "getting away with murder". In October, Reuters reported https://www.reuters.com/article/us-usa-generics/u-s-states-allege-broad-generic-drug-price-fixing-collusion-idUSKBN1D0201 a lawsuit on the price-fixing case accused 18 companies, including Mylan and Teva Pharmaceutical, and named 15 medicines.

  • Generic-Drug Companies to Face First Charges in U.S. Probe
    Bloomberg2 days ago

    Generic-Drug Companies to Face First Charges in U.S. Probe

    U.S. prosecutors are nearing their first charges against companies in an almost four-year-old criminal investigation into alleged price-fixing by generic-drug makers, according to people familiar with ...

  • MarketWatch2 days ago

    Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says

    In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.

  • American City Business Journals3 days ago

    Mylan to lay off hundreds in West Virginia

    It's one of the state's largest employers.

  • Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
    PR Newswire5 days ago

    Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting

    Three posters highlight Mylan's rigorous Glatiramer Acetate development program HERTFORDSHIRE, England , and PITTSBURGH , April 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...

  • Reuters6 days ago

    Mylan cuts 15 pct of workforce at West Virginia plant

    Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia. The company, which had faced intense criticism and political scrutiny over price hikes for its life-saving EpiPen emergency allergy treatment, said the Morgantown plant "needed to be rightsized to be less complex" for continued operations. The layoffs involved more than 400 employees represented by a United Steel Workers local union, reported WAJR, a Morgantown radio station.

  • Reuters9 days ago

    Canada seeks U.S. help to solve EpiPen shortage

    Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.

  • Investopedia9 days ago

    7 Stock Picks With Giant Upside: Goldman

    Green Pastures: DISH, AbbVie, Hasbro and other stocks are poised to flourish

  • Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
    InvestorPlace10 days ago

    Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out

    At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.

  • MARKETS: Stocks are swinging up and down on technicals while liquidity remains scarce
    Yahoo Finance Video5 hours ago

    MARKETS: Stocks are swinging up and down on technicals while liquidity remains scarce

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade
    Yahoo Finance Video9 days ago

    MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade

    Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.